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Objectives: diabetes mellitus is an increasingly common cause of end stage renal failure (ESRF) and the establishment of
adequate permanent vascular access for dialysis is a major cause of morbidity and mortality in these patients. The aim of
this study was to compare the availability of suitable vein, maturation rates, patency and complication rates of autogeneous
elbow fistulas in diabetics and non-diabetics at a single centre where an autogeneous vein only policy is employed.
Design: retrospective series.
Patients and methods: two hundred and ninety-three elbow fistulas were attempted in 232 patients over a seven year
period, [median age 60 years (range 14±94 years)], of which 210 were in non-diabetic and 83 were in diabetic patients. The
diabetic group had a significantly higher proportion of male patients (p5 0.05), peripheral vascular disease and established
ESRF.
Results: there was a trend towards a higher technical success rate in the non-diabetic group (98% versus 93%; p 0.057).
There was no significant difference between the primary failure rate, fistula maturation rate, revision rate or incidence of
complications between the two groups. Diabetes had no effect on cumulative secondary fistula patency even when stratified
for Type 1/Type 2 diabetes, female sex, old age or primary versus subsequent procedures.
Conclusion: diabetes mellitus has no significant detrimental effect on outcome following formation of autogeneous elbow
fistulas for haemodialysis.
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In the U.S.A. and Europe renal disease in diabetic
patients has become the single most important cause
of end stage renal failure (ESRF) due in part to the
increase in the number of elderly patients referred for
renal replacement therapy.1±3 A major factor contri-
buting to increased morbidity and mortality in these
patients is the establishment of adequate permanent
vascular access for haemodialysis,3,4 and the best
choice of access in diabetics remains to be defined.
Bresica±Cimino wrist fistulas, the primary access of
choice in the vast majority of patients,5 have poorer
outcomes in diabetics, with higher proportions failing
to mature adequately and lower patency rates when
compared to non-diabetic patients.6,7 This has led to
the preferential use of PTFE arteriovenous grafts as
the initial choice of access in diabetics, particularlyThis work has been presented in part to the Second International
Congress of the Vascular Access Society, London, May 2001.
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European centres,2 despite significantly lower patency
rates compared to grafts in non-diabetics.9±11 Alter-
natively, autogeneous vein elbow fistulas may over-
come problems of delayed maturation in wrist fistulas
in diabetics7 and in experienced hands these have a
high technical success rate, with superior long-term
patency and lower complication rates than PTFE arter-
iovenous grafts.5,12±14 To date however the effect of
diabetes on the outcome of autogeneous elbow fistulas
has not been well defined.
The aim of this study was to compare the availab-
ility of suitable vein, maturation rates, patency and
complication rates of autogeneous elbow fistulas
in diabetic and non-diabetic patients at a single
European centre.
Patients and Methods
Over a seven-year period (1993±2000) 293 auto-
geneous elbow fistulas were attempted in 232 patients,
of whom 164 were non-diabetic and 68 were dia-
betic (median age 60 years (range 14±94 years)).cience Ltd





BCAVF 150 (71) 64 (77)
BBAVF 60 (29) 19 (23)
Age (years) 56 (16±94) 57 (18±87)
median (range)
Male 101 (48) 51 (61)*
Female 109 (52) 32 (39)*
Left 153 (73) 60 (72)
Aspirin 26 (12) 16 (19)
Peripheral vascular disease 21 (10) 16 (19)*
Hyperlipidaemia 7 (3) 17 (21)*
Over 65 years 86 (41) 29 (35)
Previous ipsilateral 118 (56) 53 (64)
Percutaneous dialysis catheter
Primary access 65 (31) 29 (35)
Pre-ESRF 33 (16) 6 (7)*
ESRF 172 (82) 95 (90)*
Type of Anaesthesia
Local Infiltration 14 (7) 4 (5)
Regional Block 63 (30) 35 (33)
General Anaesthesia 119 (56) 42 (50)
Unknown 14 (7) 2 (2)
Percentages are in parentheses.
* p5 0.05 Pearson's Chi Square.
BCAVF, Brachiocephalic fistula, BBAVF, Transposed Brachiobasilic
fistula, (N)IDDM, (Non) insulin dependant diabetes, ESRF, End-stage
Renal Failure. Hyperlipidaemia serum cholesterol > 5.5 mmol/l or
on lipid lowering therapy, Peripheral vascular disease, non invasive
or angiographic evidence of lower limb arterial occlusive disease.
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(n 83) and non-diabetic (n 210) fistulas can be
seen in Table 1.
An autogeneous vein only policy was employed
during this time period, such that PTFE grafts were
inserted only after all autogeneous elbow fistula
options had been exhausted. Bresica-Cimino radio-
cephalic or forearm autogeneous AVF were the pri-
mary access of choice regardless of age or presence of
diabetes. Formation of a brachiocephalic elbow fistula
was the second procedure of choice in the absence of
adequate wrist vessels. Transposed brachiobasilic
arteriovenous fistulas (BB AVF) were used in the
absence of suitable superficial vein in the upper
limbs rather than Brachio-basilic forearm loop grafts.
Forearm loop grafts are considered to have inferior
patency compared to BB AVF and may in some
patients jeopardise future BB AVF construction and it
is unit policy to perform the evidence based best long-
term access at each stage of access planning. PTFE
grafts were performed in the absence of suitable basi-
lic vein. Four hundred and twenty wrist fistulas,
13 upper limb PTFE grafts and 10 lower limb PTFE
grafts were also performed during the same time
interval. Eighty three percent of these fistulas wereperformed by a single surgeon who performs the
majority of vascular access procedures at this
institution. Data was collected retrospectively from
patient case notes and the data set was 100% complete.
Preoperative/operative assessment
Before operation the adequacy of the cephalic vein
and arterial supply of the upper limb (e.g. brachial,
radial and ulnar pulses) were determined by clinical
examination. Patency of the cephalic vein was ascer-
tained throughout its length by inspection and palpa-
tion after applying a tourniquet around the most
proximal part of the upper arm. The presence of a
transmitted pulse along the vessel proximally follow-
ing percussion at the antecubital fossa was regarded
as a valuable indicator of patency. Patients with an
occluded or fibrotic segment of vein in the antecubital
fossa on clinical assessment were considered for BB
AVF. At BB AVF construction the cephalic vein was
assessed in all patients and used for a brachiocephalic
fistula construction if technically feasible. Preopera-
tive venography or venous mapping with duplex
ultrasound was not performed routinely (23%), and
in the majority of cases was to assess the central veins.
All brachiocephalic fistulas were created in the ante-
cubital fossa by an end to side anastomoses using
continuous 7/0 polypropylene sutures. BB AVF were
fashioned using a technique similar to that previously
described.15 In an attempt to reduce the incidence of
steal arteriotomy length was limited to approximately
75% or less of the proximal arterial diameter by visual
assessment. Operations were performed under local,
regional or general anaesthesia. Fistulas were allowed
at least 6 weeks to develop before venepuncture for
haemodialysis.
Definitions of patency and success
Technical success was defined as the presence of a
thrill on palpation or a bruit on auscultation 24 h
post operatively. When no attempt was made to
needle a fistula it was designated as never used. Pri-
mary failure refers to those fistulas that failed without
ever being needled for haemodialysis, including those
that were technical failures. Primary patency refers to
the duration of access patency up until the first inter-
vention to maintain patency or until fistula failure.
Cumulative secondary patency refers to fistulas
functioning for dialysis, regardless of the number of
interventions required to maintain patency. Fistula
failure was defined as inability to use the fistula forEur J Vasc Endovasc Surg Vol 23, May 2002
Table 2. Elbow fistulas never used for dialysis (n 96).
Non-diabetic Diabetic
Never Used 63 (30) 33 (40)
Primary Failure 40 (19) 21 (25)
Technical Failure 5 (2) 6 (7)
Never matured 10 (5) 4 (5)
Thrombosis 18 (9) 3 (4)
Arm oedema 3 (1) 3 (4)
Steal 2 (1) 2 (2)
Other 2 (1) 3 (4)
Transplanted 2 (1) 0
Died 7 (3) 5 (6)
Maturing 4 (2) 4 (5)
Pre-Dialysis 7 (3) 2 (2)
Converted to PD 1 (1) 0
Other 2 (1) 1 (1)
Values in parentheses represent percentage of total diabetic and
non-diabetic patients respectively.
PDPeritoneal Dialysis.
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tation or death. Operative ligations were classified as
failures. Patients who underwent renal transplan-
tation were considered as lost to follow up and not as
failures. Deaths being unrelated to fistula failure were
also treated as lost to follow up. Poor fistula flows
refer to access flows that are not high enough to sup-
port adequate dialysis (less than 350 ml/min Blood
Flow Rate in Fresenius polysulphone capillary dialy-
sers). As these are a continuum of fistula thrombosis,
these have been classified together as causes of fistula
failure. No objective fistula surveillance programme
(flow monitoring or recirculation studies) was in place
during this time period however fistula maturation
(suitability for haemodialysis) was assessed at each
dialysis session. A fistula was considered to have
matured when it provided adequate dialysis. Compli-
cation rates refer to fistula related problems only and
include the causes of fistula failure. Percutaneous
angioplasty of venous stenoses was only attempted
in 10 cases of central vein stenosis in this cohort of
patients of which function was restored in 2 cases.
Statistical analysis
Primary and secondary patency rates were calculated
by the Kaplan±Meier Actuarial Survival Analysis
method. Differences between categorical variables
were tested with Pearson's Chi-square test. Differ-
ences between means were tested with the Student's
two-tailed test (normal distribution) or Mann±
Whitney U-test (no normal distribution). Factors
affecting fistula patency and complication rates were
assessed using the log-rank test for fistula survival
curves and Chi-squared tests for univariate risk factor
analysis. A p value of less than 0.05 was considered
statistically significant. Factors influencing fistula
patency were analysed in a Cox Proportional Hazards
model. Calculations were made with the help of the
Statistical Package for the Social Sciences (SPSS 9-0,
Chertsey, U.K.)
Results
There was a trend towards a higher technical success
rate in the non-diabetic group although this was not
statistically significant (2% versus 7%, p 0.06,
Table 2). Technical failure was due to sclerosed or
thrombosed veins at operation in virtually every case.
A larger proportion of AVFs in non-diabetics was
eventually used for dialysis however this was notEur J Vasc Endovasc Surg Vol 23, May 2002significant and was not attributable to a higher
primary failure rate (Table 2). In particular there was
no difference in the proportion of AVF in diabetic and
non-diabetic patients that failed to mature adequately
for dialysis.
Patency
There was no difference in the primary or secondary
patency between diabetic and non-diabetic AVF
(Fig. 1) or in the number of revision procedures per-
formed to maintain patency (Table 3). As the number
of revision procedures was low primary and second-
ary patency rates were essentially the same. Cumula-
tive secondary patency for diabetics and non-diabetics
was 64% and 59% at 1 year and 40% and 39% at 3 years
respectively. The causes of fistula failure are listed in
Tables 2 and 3. There was no difference in cumulative
secondary patency rates for diabetic and non-diabetic
patients even when stratified for age (over 65, NS, log
rank, p 0.44), female sex (NS, log rank, p 0.49) or
primary access versus subsequent procedures (NS, log
rank, p 0.44) (Table 4). There was also no difference
in patency between insulin dependant and non-
insulin dependant diabetics (NS, log rank, p 0.23).
Diabetes also had no effect on patency when
brachiobasilic and brachiocephalic AVF were consid-
ered separately (log rank p 0.40). Using the Cox
proportional hazards model diabetes, age over 65
years and sex were found to have no independent
effect on the risk of fistula failure (Table 5). Prior
ipsilateral subclavian vein temporary dialysis catheter
was the only factor found to have an independent
effect on the risk of fistula failure.
Table 4. Calculated Kaplan±Meier survival probabilities for auto-
geneous elbow fistulas at 1 year stratified for age, sex, type and
order of access construction.
Stratification 1 Year Patency SE (n)
Non DM DM
Over 65 years
Y 0.56 0.06 (32) 0.59 0.09 (13)
N 0.68 0.05 (55) 0.59 0.08 (20)
Male
Y 0.61 0.06 (36) 0.69 0.07 (19)
N 0.64 0.05 (50) 0.47 0.09 (13)
Primary Access
Y 0.67 0.07 (27) 0.67 0.09 (15)
N 0.61 0.04 (60) 0.55 0.07 (17)
BC AVF 0.65 0.04 (64) 0.61 0.07 (67)
BB AVF 0.63 0.07 (28) 55 0.1 (5)
Patency, Kaplan±Meier survival probability ratio, SE, Standard
Error, n, Number of fistulas at risk.
Fig. 1. Cumulative Patency for autogeneous elbow fistulas in diabetic and (filled triangles) non-diabetic patients (open triangles).
Table 3. Outcome in patients with autogeneous elbow fistulas
used for dialysis (n 197).
Non-diabetic Diabetic
Used for Dialysis 147 50
Failed 52 (35) 16 (32)
Thrombosis 38 (26) 13 (26)
Steal 1 (1) 2 (4)
Arm oedema 6 (4) 1 (2)
Aneurysm 5 (3) 0
Other 2 (1) 0
Transplanted 14 (10) 5 (10)
Died 21 (14) 10 (20)
Revision 19 (13) 9 (18)
Values in parentheses represent percentage of those fistulas used for
dialysis only. There were no significant differences between the two
groups.
Number of fistula under risk
non DM 147 87 43 11
DM 50 29 12 3
Time post
fistula formation
Primary Patency SE (n) Secondary Patency SE (n)
Non DM DM Non DM DM
1 year 0.62 0.04 (88) 0.54 0.06 (26) 0.64 0.04 (88) 0.59 0.06 (26)
3 year 0.39 0.05 (9) 0.39 0.1 (4) 0.40 0.05 (13) 0.39 0.1 (4)
Patency, Kaplan±Meier survival probability ratio, SE, Standard Error, n, Number of fistulas at risk.
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Table 6. Complications in diabetic and non-diabetic patients with
autogeneous elbow fistulas (n 293).
Non-diabetic Diabetic
Total 127 (61) 42 (51)
Early thrombosis 13 (6) 2 (2)
Arm oedema 32 (10) 10 (12)
Slow to develop 24 (11) 10 (12)
Venous hypertension 15 (7) 5 (6)
Steal 17 (8) 11 (13)
Wound infection 8 (4) 6 (7)
Late infection 13 (6) 0*
Bleeding 13 (6) 3 (4)
Aneurysm 12 (5) 1 (1)*
Cardiac failure 2 (1) 0
Percentages in parentheses.
Some patients had more than one complication.
* p5 0.05 Pearson's Chi square.
Table 5. Cox regressional analysis of factors influencing fistula
failure.




0.6697 0.2966 1 0.0240 1.0707
Diabetic ÿ0.3561 0.3531 1 0.3133 0.0000
MALE 0.0452 0.0299 1 0.8628 0.0000
Over 65 0.2182 0.2723 1 0.4229 0.0000
Pre-ESRF ÿ0.0881 0.4301 1 0.8376 0.0000
PVD ÿ0.7826 0.5078 1 0.1232 ÿ0.0246
Type of Anaesthesia 0.1168 0.1411 1 0.4076 0.0000
Primary Access 0.3713 0.3457 0.2828 0.0000
Hyperlipidaemia 0.7549 0.5306 1 0.1548 0.0062
SE, Standard Error, Sig, two tailed level of significance, R, Regres-
sion Coefficient, df, degrees of freedom.
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There was no statistically significant difference in the
overall incidence of complications between the two
groups (Table 6) although there was a non-statistically
significant increase in the incidence of steal in diabetic
patients (p 0.22). In addition there was a higher
incidence of aneurysm formation and haemorrhage
in the non-diabetic group with a significantly higher
incidence of AVF infection related to aneurysm forma-
tion and secondary haemorrhage. There was a slightly
higher overall mortality in the diabetic group (Table 3)
but cumulative patient survival was not significantly
different (NS, log rank, p 0.12).
Discussion
Main findings of the study
These data demonstrate that autogeneous elbow fistu-
las are technically successful in the vast majority of dia-
betic patients (93% in this series) and have equivalent
maturation and patency rates compared to non-
diabetics with no significant increase in the incidence
of complications.
Strengths and weakness of the study
The analysis was limited for a number of reasons. (1) It
was retrospective. (2) The primary failure rate was
high and the cumulative elbow fistula patency rate
was low in comparison to some other series (36±67%
secondary patency at three years reported in the lit-
erature12±14 although this can be attributed to the high
proportions of patients who had prior subclavian
haemodialysis catheters or were undergoing second-
ary or tertiary access procedures. In addition primary
failures were not included in patency calculations in
these earlier studies. It is also possible that our policy
of limiting the length of the arteriotomy in brachial
artery to less than approximately 75% or less of the
proximal arterial diameter could contribute to lower
patency. This policy resulted in a lower incidence of
steal however (less than 8% overall compared to
10±20% in other series.12±14 (3) A significantly lower
proportion of women in the diabetic group may have
influenced the results, although patency rates in this
study were no different between the two groups when
stratified for sex. Most studies that have suggested a
poorer outcome in women with AVF have largely
considered only wrist fistulas,16,17 and one interpreta-
tion of this data is that inferior outcomes in women areEur J Vasc Endovasc Surg Vol 23, May 2002due largely to smaller vessels at the wrist,17 a problem
that is largely absent at the elbow.
Results in relation to other studies
In clinical practice the selection of the type of vascular
access depends on the timing of placement, the skills
and experience of the operating surgeon, the quality
of superficial veins and the cardiovascular status of
the patient. Diabetic patients present a particular chal-
lenge as they are often considered to be unsuited to
autogeneous vein fistulas. This is supported by a
recent report from the United States Renal Data Regis-
try identified diabetes as an independent risk factor
for a patient to have a PTFE graft as their primary
access.8 This is contrary to published recommenda-
tions regarding vascular access planning5 and occurs
in spite of significantly poorer outcomes with PTFE
grafts in diabetics in comparison to autogeneous vein
fistulas or to PTFE grafts in non-diabetics.9±11 The
preference for PTFE grafts in diabetics is due to a
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diabetic patients presenting for primary access with
established ESRF who require a functioning access
with a short maturation time, and the relatively low
rate of primary failure (5±15%)18 associated with PTFE
grafts. In addition autogeneous wrist fistulas have
high levels of inadequate maturation (30±80%) as
well as lower patency in diabetics attributed to
high levels of pre-existing intimal hyperplasia and
atheroma in distal veins and arteries respectively,6,7
although this is by no means a universal finding.17,18
Overall autogeneous vein fistulas do have better
patency compared to AV grafts in diabetics9,10 and
the preferential choice of PTFE grafts in many cases
reflects a lack of experience with autogeneous vein
fistulas, particularly more proximally.19 In this study
at a single centre utilising an autogeneous vein only
policy, diabetes had no effect on the outcome of auto-
geneous elbow fistulas. This can be potentially
explained by higher blood flows along with reduced
medial calcification in more proximal vessels, as well
as reduced technical difficulty due to larger vessels at
the elbow. Along with a recent report by Haikaim
et al.7 where autogeneous elbow AVF had lower
primary failure rates and superior patency compared
to wrist fistulas in diabetics, this study supports the
view that autogeneous elbow fistulas may be the pri-
mary access of choice in diabetics. In view of the many
studies suggesting that diabetes has no adverse effect
on the outcome of autogeneous wrist fistulas17,18 how-
ever further prospective trials of these two types of
access in diabetic patients are required.
Conclusions
This study suggests that the insertion of PTFE arter-
iovenous grafts can be avoided in the vast majority of
diabetic patients, even where wrist vessels are inade-
quate. Furthermore, unlike other forms of access
(Bresica±Cimino fistulas and AV Grafts), diabetes has
no adverse effect on the outcome of autogeneous
elbow fistulas. The wider introduction of autogeneous
elbow fistulas in this group of patients may reduce
morbidity as well as potentially reducing healthcare
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